 |
(NaturalNews) What investors had hoped would build into yet another 2.68 percent dividend yield for pharmaceutical behemoth Eli Lilly has turned into a massive financial letdown after trials of solanezumab, a supposedly promising experimental drug for Alzheimer’s disease and other forms of dementia, showed less than favorable efficacy in the latest clinical trials. Reports indicate... |
Big pharma: Eli Lilly stock erases 6 years of dividends after failed drug trial
Continue Reading
Bagikan Berita Ini
Related Posts :
Long-term food independence: Fruit trees are a critical prep before SHTF- Patrick Byrne, CEO of Overstock, resigns after making Deep State admissions in bizarre “Spygate” scandal twist
- Unlocking the secrets of Ancient Egypt: Archaeologists uncover dozens of mummified animals in the Tomb of Tutu
- Greener and cleaner: Can "green" roofs planted with vegetation minimize indoor air pollution?
- This could trigger civil war in America! The party of death and destruction's hatred of whites, Christians, conservatives and Trump supporters could lead to their own annihilation
0 Response to "Big pharma: Eli Lilly stock erases 6 years of dividends after failed drug trial"
Post a Comment